Sam Brusco, Associate Editor05.24.23
Abbott has released new data from an investigator-sponsored European trial showing that managing indicated heart failure patients with its CardioMEMS HF system resulted in significant improvement in patient-reported quality of life scores as early as three months after using the remote monitoring sensor.
The MONITOR-HF trial also resulted in a 44% reduction in heart-failure related hospitalizations among heart failure patient using guideline-directed medical therapy (GDMT). MONITOR-HF is the third randomized, controlled trial worldwide to demonstrate significant health benefit and quality of life improvement for heart patients using the CardioMEMS HF system.
Heart failure participants who received a CardioMEMS sensor reported a clinically meaningful improvement in their quality of life as quantified by a seven-point mean increase on the Kansas City Cardiomyopathy Questionnaire's (KCCQ) score compared to patients in the control group, who didn’t receive the pressure sensor and whose scores decreased.
The MONITOR-HF trial enrolled 348 patients in 25 sensors in the Netherlands.
"The Dutch health care system is known for its structured approach to heart failure management at outpatient clinics with general access to guideline-directed medical therapies," J.J. (Jasper) Brugts, M.D., Ph.D., principal investigator for the MONITOR-HF trial and associate professor at Erasmus Medical Center in Rotterdam, Netherlands, told the press. "This approach raises the bar, making the MONITOR-HF results even more meaningful given that patients who were already receiving a high standard of care reported significant improvements in their quality-of-life while using the CardioMEMS monitoring system."
CardioMEMS is a paperclip-sized device that after placement in the pulmonary artery in a minimally invasive procedure monitors pressure changes indicating worsening heart failure. It wirelessly sends daily readings to the patient’s clinical team.
"Heart Failure is a global health problem with a devastating impact on patient lives and high rate of morbidity and mortality," said Philip B. Adamson, M.D., chief medical officer of Abbott's heart failure business. "These results demonstrate once again that a proactive, remote-centered approach using pressure monitoring with CardioMEMS leads to better health outcomes and higher patient satisfaction across multiple health indicators than medication alone."
The MONITOR-HF trial also resulted in a 44% reduction in heart-failure related hospitalizations among heart failure patient using guideline-directed medical therapy (GDMT). MONITOR-HF is the third randomized, controlled trial worldwide to demonstrate significant health benefit and quality of life improvement for heart patients using the CardioMEMS HF system.
Heart failure participants who received a CardioMEMS sensor reported a clinically meaningful improvement in their quality of life as quantified by a seven-point mean increase on the Kansas City Cardiomyopathy Questionnaire's (KCCQ) score compared to patients in the control group, who didn’t receive the pressure sensor and whose scores decreased.
The MONITOR-HF trial enrolled 348 patients in 25 sensors in the Netherlands.
"The Dutch health care system is known for its structured approach to heart failure management at outpatient clinics with general access to guideline-directed medical therapies," J.J. (Jasper) Brugts, M.D., Ph.D., principal investigator for the MONITOR-HF trial and associate professor at Erasmus Medical Center in Rotterdam, Netherlands, told the press. "This approach raises the bar, making the MONITOR-HF results even more meaningful given that patients who were already receiving a high standard of care reported significant improvements in their quality-of-life while using the CardioMEMS monitoring system."
CardioMEMS is a paperclip-sized device that after placement in the pulmonary artery in a minimally invasive procedure monitors pressure changes indicating worsening heart failure. It wirelessly sends daily readings to the patient’s clinical team.
"Heart Failure is a global health problem with a devastating impact on patient lives and high rate of morbidity and mortality," said Philip B. Adamson, M.D., chief medical officer of Abbott's heart failure business. "These results demonstrate once again that a proactive, remote-centered approach using pressure monitoring with CardioMEMS leads to better health outcomes and higher patient satisfaction across multiple health indicators than medication alone."
